Redsense has secured a new order worth MSEK 6.99

Redsense Medical has received a new order valued at MSEK 6.99 from one of its U.S. distributors This order reflects a step in our strategy to better align our sales with the needs of our end consumers.

"We are glad to receive this new order and that we have been able to ship it all, in June, which underscores our dedication to operational excellence. We have an ambition to continue with this approach of getting more frequent orders to be able to further align our sales with the sales to the end consumers, this allows us to respond more effectively to market demands, " said Jennie Kardell, CEO of Redsense Medical AB.

 Contact information

For more information, please contact: 
Jennie Kardell
CEO
Telephone: +46 72-171 1264
E-mail: jennie.kardell (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.